Condition: Prostate Cancer · Prostate Cancer Metastatic Disease · Prostate Cancer Recurrent · Sponsor: Maastricht Radiation Oncology
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.
This description comes directly from the study's public registry record.
Iris EWG Laven, PhD · 0031(0)884455666 · iris.laven@maastro.nl
Chantal Overhof, BEc · 0031(0)884455666 · groepcto@maastro.nl
Always discuss trial participation with your own doctor first.
| Zuyderland Medisch Centrum | Heerlen, Limburg, Netherlands | Not Yet Recruiting |
| Academisch Ziekenhuis Maastricht | Maastricht, Limburg, Netherlands | Not Yet Recruiting |
| Maastricht Radiation Oncology | Maastricht, Limburg, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07004582